195 related articles for article (PubMed ID: 1808464)
1. Pharmacodynamic and protective properties of a murine lipopolysaccharide-specific monoclonal antibody in experimental Pseudomonas aeruginosa pneumonia in mice.
Oishi K; Sonoda F; Miwa H; Tanaka H; Watanabe K; Matsumoto K; Pollack M
Microbiol Immunol; 1991; 35(12):1131-41. PubMed ID: 1808464
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia.
Oishi K; Sonoda F; Iwagaki A; Ponglertnapagorn P; Watanabe K; Nagatake T; Siadak A; Pollack M; Matsumoto K
Antimicrob Agents Chemother; 1993 Feb; 37(2):164-70. PubMed ID: 8383936
[TBL] [Abstract][Full Text] [Related]
4. Effects of the combination of lipopolysaccharide-specific monoclonal antibodies and sparfloxacin against Pseudomonas aeruginosa pneumonia in neutropenic mice.
Oishi K; Sonoda F; Iwagaki A; Kobayashi S; Nagatake T; Matsumoto K
Antimicrob Agents Chemother; 1992 Jul; 36(7):1352-7. PubMed ID: 1324643
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.
Pennington JE; Small GJ; Lostrom ME; Pier GB
Infect Immun; 1986 Oct; 54(1):239-44. PubMed ID: 3093385
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime.
Akiyama M; Oishi K; Tao M; Matsumoto K; Pollack M
Microbiol Immunol; 2000; 44(8):629-35. PubMed ID: 11021392
[TBL] [Abstract][Full Text] [Related]
7. Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody.
Hector RF; Collins MS; Pennington JE
J Infect Dis; 1989 Sep; 160(3):483-9. PubMed ID: 2760499
[TBL] [Abstract][Full Text] [Related]
8. Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide.
Stoll BJ; Pollack M; Young LS; Koles N; Gascon R; Pier GB
Infect Immun; 1986 Sep; 53(3):656-62. PubMed ID: 2427453
[TBL] [Abstract][Full Text] [Related]
9. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
Sawa T; Ito E; Nguyen VH; Haight M
Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
[TBL] [Abstract][Full Text] [Related]
10. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
[TBL] [Abstract][Full Text] [Related]
11. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
12. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.
Hemachandra S; Kamboj K; Copfer J; Pier G; Green LL; Schreiber JR
Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa.
Sawada S; Kawamura T; Masuho Y; Tomibe K
J Infect Dis; 1985 Nov; 152(5):965-70. PubMed ID: 3930629
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of prophylaxis and therapy against gram-negative infections by human monoclonal antibodies.
Lang AB; Fürer E; Cryz SJ
FEMS Immunol Med Microbiol; 1993 Jun; 7(1):9-13. PubMed ID: 8364527
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies against lipopolysaccharide protect against
Kang J; Mateu-Borrás M; Monroe HL; Sen-Kilic E; Miller SJ; Dublin SR; Huckaby AB; Yang E; Pyles GM; Nunley MA; Chapman JA; Amin MS; Damron FH; Barbier M
Front Cell Infect Microbiol; 2023; 13():1191806. PubMed ID: 37424774
[No Abstract] [Full Text] [Related]
16. An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model.
Patel A; DiGiandomenico A; Keller AE; Smith TRF; Park DH; Ramos S; Schultheis K; Elliott STC; Mendoza J; Broderick KE; Wise MC; Yan J; Jiang J; Flingai S; Khan AS; Muthumani K; Humeau L; Cheng LI; Wachter-Rosati L; Stover CK; Sardesai NY; Weiner DB
Nat Commun; 2017 Sep; 8(1):637. PubMed ID: 28935938
[TBL] [Abstract][Full Text] [Related]
17. Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa.
Pennington JE
J Infect Dis; 1979 Jul; 140(1):73-80. PubMed ID: 110888
[TBL] [Abstract][Full Text] [Related]
18. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.
Pennington JE; Pier GB; Sadoff JC; Small GJ
Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209
[TBL] [Abstract][Full Text] [Related]
19. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa.
Collins MS; Ladehoff DK; Mehton NS; Noonan JS
FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368
[TBL] [Abstract][Full Text] [Related]
20. Protection of immunosuppressed mice against infection with pseudomonas aeruginosa by monoclonal antibodies to outer membrane protein OprI.
Rahner R; Eckhardt A; Duchêne M; Domdey H; von Specht BU
Infection; 1990; 18(4):242-5. PubMed ID: 2120132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
